Pediatric tuberculosis (TB) is a major but frequently under-recognized global health burden, contributing to 1.5 million new cases annually and ranking among the top 10 causes of childhood mortality. The COVID-19 pandemic severely disrupted TB diagnosis and treatment access, worsening outcomes—especially in children under 5, who account for 80% of pediatric TB deaths due to their immunological vulnerability.
Highlights:
- Diagnosis is often complicated by the predominance of paucibacillary and extrapulmonary presentations in children.
- Tools like IGRA and Xpert Mtb/RIF Ultra accelerate diagnosis and drug-resistance detection.
- Emerging evidence suggests that the gut–lung microbiota axis and vitamin D status may modulate TB susceptibility and therapeutic outcomes.
- Shorter regimens for latent and non-severe TB improve adherence, while newer drugs such as bedaquiline and delamanid are now approved for pediatric drug-resistant TB.
- While the BCG vaccine offers some protection against severe disease, it does not prevent latent TB reactivation, reinforcing the urgent need for next-generation vaccines.
What sets this study apart:
This review integrates epidemiologic trends, microbiome science, diagnostic advances, and novel therapeutics into a comprehensive approach to pediatric TB management. It highlights both biologic complexity and systemic barriers, particularly in resource-limited settings.
Limitations:
TB remains difficult to detect in children under 2 and often mimics other conditions. Managing drug-resistant TB is further complicated by low bacterial burden and limited pediatric formulations.
Are current tools sufficient for timely and accurate TB diagnosis in children? Could understanding the microbiota–immunity interaction reshape pediatric TB therapy?
